GILD — Gilead Sciences Income Statement
0.000.00%
Last trade - 00:00
- $103.10bn
- $123.59bn
- $27.12bn
- 90
- 54
- 79
- 87
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 22,449 | 24,689 | 27,305 | 27,281 | 27,116 |
Cost of Revenue | |||||
Gross Profit | 18,423 | 20,117 | 20,704 | 21,624 | 21,097 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 18,162 | 20,618 | 17,387 | 19,951 | 19,511 |
Operating Profit | 4,287 | 4,071 | 9,918 | 7,330 | 7,605 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 5,160 | 1,669 | 8,278 | 5,814 | 6,859 |
Provision for Income Taxes | |||||
Net Income After Taxes | 5,364 | 89 | 6,201 | 4,566 | 5,612 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 5,386 | 123 | 6,225 | 4,592 | 5,664 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 5,386 | 123 | 6,225 | 4,592 | 5,665 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 5.26 | 4.73 | 5.07 | 6.78 | 6.15 |
Dividends per Share |